Sulfur hexafluoride

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sulfur hexafluoride
Accession Number
DB11104
Type
Small Molecule
Groups
Approved
Description

Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

Structure
Thumb
Synonyms
  • hexafluoridosulfur
  • Sulfur fluoride
  • Sulfur hexafluoride
  • sulfur(6+) fluoride
  • sulfur(VI) fluoride
  • Sulphur hexafluoride
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SonovuePowder, for suspensionIntravenousBracco Imaging S.P.A.2016-09-22Not applicableCanada
SonovueInjection, powder, for solution8 μl/mlIntravenousBracco International B.V.2001-03-26Not applicableEu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
LumaSonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)KitIntravenous; IntravesicalBracco Diagnostics Inc2015-01-15Not applicableUs
LumaSonSulfur hexafluoride (60.7 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg)KitIntravenous; IntravesicalBracco Suisse SA2015-01-15Not applicableUs
Categories
UNII
WS7LR3I1D6
CAS number
2551-62-4
Weight
Average: 146.05
Monoisotopic: 145.962490152
Chemical Formula
F6S
InChI Key
SFZCNBIFKDRMGX-UHFFFAOYSA-N
InChI
InChI=1S/F6S/c1-7(2,3,4,5)6
IUPAC Name
hexafluoro-λ⁶-sulfane
SMILES
FS(F)(F)(F)(F)F

Pharmacology

Indication

Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.

Pharmacodynamics

Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended). For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.

Mechanism of action

Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.

Volume of distribution

In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.

Protein binding
Not Available
Metabolism

SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.

Route of elimination

The SF6 component of Lumason is eliminated via the lungs.

Half life

The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. FDA label [Link]
External Links
KEGG Drug
D05962
PubChem Compound
17358
PubChem Substance
347827897
ChemSpider
16425
ChEBI
30496
ChEMBL
CHEMBL1796998
Wikipedia
Sulfur_hexafluoride
ATC Codes
V08DA05 — Sulfur hexafluoride
AHFS Codes
  • 36:89.00* — Other Diagnostics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDevice FeasibilityStroke, Acute1
0Enrolling by InvitationDiagnosticProliferative Breast Disease1
0Not Yet RecruitingDiagnosticAsbestosis / Asthma / Bronchiectasis / Chronic Obstructive Pulmonary Disease (COPD) / Cold Virus / Cystic Fibrosis (CF) / Emphysema / Interstitial Lung Disease (ILD) / Lung Cancers / Lung Infection / Lung Resection / Lung Transplant / Mesothelioma / OSAS (Obstructive Sleep Apneas Syndrome) / Pulmonary Dysplasia / Pulmonary Embolism / Pulmonary Fibrosis / Pulmonary Hypertension (PH) / Seasonal Allergies1
0RecruitingDiagnosticDevelopmental Dysplasia of the Hip (DDH)1
0RecruitingScreeningDiseases of Liver / Hepatocellular,Carcinoma / Liver Cirrhosis1
1Not Yet RecruitingDiagnosticAppendicitis Acute1
1Not Yet RecruitingDiagnosticVesico-Ureteral Reflux1
1RecruitingBasic ScienceAtherosclerosis of Artery / Fibromuscular Dysplasia of Arteries / Segmental Arterial Mediolysis / Spontaneous Coronary Artery Dissection1
1RecruitingDiagnosticTransplantation, Kidney1
1, 2RecruitingDiagnosticAbdominal Injuries1
1, 2RecruitingTreatmentNeoplasms, Breast / Neoplasms, Colorectal1
1, 2WithdrawnDiagnosticCoronary Artery Disease1
2CompletedNot AvailablePulmonary Hypertension (PH)1
2CompletedDiagnosticUrinary Tract Infection / Vesicoureteral Reflux1
2Not Yet RecruitingTreatmentPancreatic Ductal Carcinoma1
2RecruitingBasic ScienceCarotid Artery Plaque1
2RecruitingDiagnosticAppendicitis Acute1
2RecruitingDiagnosticChronic Kidney Disease (CKD) / Von-Hippel Lindau1
3CompletedDiagnosticAtherosclerosis / Carotid Artery Plaque / Stroke, Ischemic1
3CompletedDiagnosticCoronary Artery Disease2
3CompletedDiagnosticLiver Lesions1
3CompletedDiagnosticNeoplasms, Hepatic2
3CompletedTreatmentRetinal Detachment / Vitreoretinopathy, Proliferative1
3RecruitingDiagnosticBowel Ischemic / Necrotizing Enterocolitis of Newborn1
3RecruitingDiagnosticBrain Ischemia Hypoxia / Hypoxic-Ischaemic Encephalopathy1
3RecruitingDiagnosticHepatocellular,Carcinoma / Liver Cirrhosis1
3RecruitingOtherPregnancy1
3RecruitingTreatmentEarly Primary Breast Cancer1
3TerminatedDiagnosticCongenital Heart Disease (CHD)1
3TerminatedDiagnosticProstate Cancer1
3TerminatedTreatmentStroke, Ischemic1
4Enrolling by InvitationDiagnosticCrohn's Disease (CD)1
4Not Yet RecruitingDiagnosticBone Marrow Transplant Complications / Sinusoidal Obstruction Syndrome / Stem Cell Transplant Complications / Veno Occlusive Disease, Hepatic1
4Not Yet RecruitingDiagnosticRenal Cancers1
4Not Yet RecruitingDiagnosticRenal Malignant Tumor1
4RecruitingDiagnosticAbdominal Injuries / Accidental Fall / Motor Vehicle Injury / Physical Abuse1
4RecruitingDiagnosticTrauma Abdomen1
4TerminatedDiagnosticLiver Biopsy1
4WithdrawnDiagnosticNeonatal Post-Hemorrhagic Hydrocephalus1
Not AvailableCompletedNot AvailableReperfusion Injury1
Not AvailableCompletedDiagnosticAdenocarcinoma of the Pancreas1
Not AvailableCompletedDiagnosticAtherosclerosis / Carotid Artery Stenosis1
Not AvailableCompletedDiagnosticPlacenta Accreta1
Not AvailableCompletedDiagnosticTumors, Breast1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD)1
Not AvailableRecruitingNot AvailableHematoma1
Not AvailableRecruitingDiagnosticProstate Cancer / Prostatic Neoplasms1
Not AvailableTerminatedDiagnosticProstate Cancer1
Not AvailableUnknown StatusDiagnosticMalignant Neoplasm, Overlapping Lesion of Breast1
Not AvailableUnknown StatusDiagnosticMetastatic Cancers / Renal Cancers1
Not AvailableUnknown StatusTreatmentHydrops in Keratoconus1
Not AvailableUnknown StatusTreatmentRhegmatogenous Retinal Detachments1
Not AvailableWithdrawnDiagnosticHepatocellular,Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitIntravenous; Intravesical
Injection, powder, for solutionIntravenous8 μl/ml
Powder, for suspensionIntravenous
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5686060No1997-11-112017-11-11Us
US10232061No2018-07-062038-07-06Us
US10335502No2018-07-062038-07-06Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity18.44 m3·mol-1ChemAxon
Polarizability7.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as other non-metal halides. These are inorganic compounds containing 'other non-metals' and halogen.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Other non-metal halides
Sub Class
Not Available
Direct Parent
Other non-metal halides
Alternative Parents
Not Available
Substituents
Other non-metal halide
Molecular Framework
Not Available
External Descriptors
sulfur coordination entity (CHEBI:30496)

Drug created on December 03, 2015 09:51 / Updated on November 19, 2019 16:50